( ANAHEIM Calif.--(BUSINESS WIRE)--May 2...)Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer,Health

ANAHEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Antigenics Inc. (NASDAQ: AGEN) today announced additional follow-up data on the company's Phase 3 investigational therapeutic cancer vaccine Oncophage(R) (vitespen). The end-of-study results, which reflect an additional 17 months' data collection, showed that in a substantial subset of patients (n = 362) at intermediate risk for disease recurrence, Oncophage demonstrated a clinically significant improvement in recurrence-free survival (RFS) of approximately 45 percent (P less than 0.01; hazard ratio (HR) = 0.55). In addition, updated analysis in this group of patients revealed a new potential benefit associated with Oncophage treatment: for intermediate-risk patients there was a trend towards improved overall survival, the study's secondary endpoint. Furthermore, the positive overall survival trend observed to date correlates with the RFS improvement demonstrated in previous analyses. This is the largest, randomized Phase 3 kidney cancer trial ever completed in the adjuvant treatment setting.

Christopher G. Wood, MD, associate professor of urology at M. D. Anderson Cancer Center in Houston, presented the Phase 3 end-of-study results at the annual meeting of the American Urological Association (AUA; abstract #633).

"These results continue to underscore the significant potential benefit of Oncophage in a well-defined, clinically and biologically relevant subset of patients who are the most appropriate candidates for cancer vaccines," said Dr. Wood. "In addition, there are currently no approved therapies for these patients, which represent a growing and significant population due to increased use of early detection techniques."

"We are particularly encouraged to see that the clinically significant trend observed from our earlier analysis has been strengthened by the updated data from an additional 17-month follow-up of patients," said Garo H. Armen, Ph
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Protox Announces Positive Clinical Data from Prostate Cancer Study
7. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
8. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
9. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
10. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer